Transpire Bio

Transpire Bio is a clinical-stage, revenue-generating biopharmaceutical company headquartered in Florida, focused on inhalation drug delivery. The company leverages proprietary technology platforms—including dry powder inhalers and soft-mist inhalers—to develop both innovative, branded medicines and complex generic alternatives for respiratory and systemic diseases. Transpire Bio's pipeline targets serious conditions such as Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Arterial Hypertension (PAH), obesity, Parkinson's Disease Psychosis, and glioblastoma. The company maintains state-of-the-art manufacturing facilities in the U.S. and recently expanded its R&D footprint with a satellite facility in Shanghai, China, to support global market development.